Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
14.33
-0.01 (-0.07%)
Mar 4, 2026, 4:00 PM EST - Market closed
Amicus Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Amicus Therapeutics stock have an average target of 27.25, with a low estimate of 11 and a high estimate of 108. The average target predicts an increase of 90.16% from the current stock price of 14.33.
Analyst Consensus: Buy
* Price targets were last updated on Jan 22, 2026.
Analyst Ratings
The average analyst rating for Amicus Therapeutics stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 1 | 1 | 1 |
| Buy | 4 | 4 | 4 | 3 | 3 | 2 |
| Hold | 1 | 1 | 1 | 5 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 9 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $16 → $15 | Strong Buy → Hold | Downgrades | $16 → $15 | +1.19% | Jan 22, 2026 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $17 → $15 | Buy → Hold | Downgrades | $17 → $15 | +1.19% | Dec 29, 2025 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $17 → $15 | Strong Buy → Hold | Downgrades | $17 → $15 | +1.19% | Dec 22, 2025 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 19, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades $21 → $15 | Buy → Hold | Downgrades | $21 → $15 | +1.19% | Dec 19, 2025 |
Financial Forecast
Revenue This Year
764.22M
from 634.21M
Increased by 20.50%
Revenue Next Year
906.32M
from 764.22M
Increased by 18.59%
EPS This Year
0.34
from -0.09
EPS Next Year
0.68
from 0.34
Increased by 97.79%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 822.2M | 989.2M | |||
| Avg | 764.2M | 906.3M | |||
| Low | 721.2M | 829.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 29.6% | 29.4% | |||
| Avg | 20.5% | 18.6% | |||
| Low | 13.7% | 8.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.58 | 0.92 | |||
| Avg | 0.34 | 0.68 | |||
| Low | 0.24 | 0.30 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 170.7% | |||
| Avg | - | 97.8% | |||
| Low | - | -11.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.